Accumulating evidence suggests that insulin-like growth factor-I (IGF-I) and estradiol interact to regulate neural function. In this review, we focus on the cellular and molecular mechanisms involved in this interaction. The expression of estrogen receptors (ERs) and IGF-I receptor is cross-regulated in the central nervous system and many neurons and astrocytes coexpress both receptors. Furthermore, estradiol activates IGF-I receptor and its intracellular signaling. This eVect may involve classical ERs since recent Wndings suggest that ER may aVect IGF-I actions in the brain by a direct interaction with some of the components of IGF-I signaling. In turn, IGF-I may regulate ER transcriptional activity in neuronal cells. In conclusion, ERs appear to be part of the signaling mechanism of IGF-I, and IGF-I receptor part of the mechanism of estradiol signaling in the nervous system.
Introduction
Evidence has accumulated over the past years indicating a close interdependence between the actions of insulin-like growth factor-I (IGF-I) and estradiol in the brain. Both factors have in common the duality of being hormones as well as locally produced neuromodulators and both exert similar pleiotropic actions in the developing and adult brain. During the development of the nervous system, IGF-I and estradiol interact to promote the diVerentiation and survival of speciWc neuronal populations. In the adult brain, IGF-I and estradiol interact to regulate neural function, neuroendocrine events, reproductive behaviors, synaptic plasticity, neurogenesis and the response of neural tissue to injury.
In this review, we will focus on the cellular and molecular mechanisms involved in this interaction. It should be noted that the cross-talk between the signaling of estradiol and IGF-I are not a peculiarity of neural tissue, since both factors interact in other cellular systems as well [4, 64, 82, 112] . Among the most studied examples are breast cancer cells, where IGF-I and estradiol have synergistic interactions in the activation of cell cycle components, resulting in increased proliferation rates [71, 134] . The crosstalk between the receptors for estradiol and IGF-I in breast cancer cells and uterine tissue shows many similarities to that observed in neural cells. Therefore, it is possible that at least part of the molecular interactions reviewed here between IGF-I and estradiol in the brain may represent a general mechanism operating in diVerent tissues.
Mechanisms of action of IGF-I and estradiol in the brain
The IGF-I receptor, a tyrosine-kinase membrane receptor, is widely expressed in the brain, which also expresses IGF-I and IGF binding proteins [15, 37] . As in other tissues, IGF-I receptors signal in the brain, through two major pathways, the mitogen-activated protein kinase (MAPK) pathway, and the phosphatidylinositol 3-kinase (PI3K)/ Akt/glycogen synthase kinase 3 (GSK3) pathway [15, 22] . IGF-I and its receptors are expressed at high levels by neurons and glia in the developing rodent brain. However, in adult rats the expression of IGF-I is dramatically reduced in many brain areas [44, 61] , excluding the hypothalamus and the median eminence where IGF-I levels increase with puberty [39, 56, 95] . In contrast to the decrease in local IGF-I production, the expression of IGF-I receptor is maintained in neurons and glia in the adult rat brain [62] . This suggests that peripheral rather than locally formed IGF-I is acting on brain IGF-I receptors in most brain areas in the adult life, at least under physiological conditions [126, 127] .
IGF-I exerts diVerent eVects on the development and plasticity of the nervous system. As in other organs, the actions of IGF-I in the brain may be aVected by the interaction with other molecules. These include neurotransmitters, neuromodulators, cytokines, hormones and other growth factors. Neurotransmitters, such as glutamate, may aVect the actions of IGF-I in the brain by interfering with the signaling of IGF-I receptor. Indeed, it has been recently shown that glutamate, at high concentrations, induces loss of sensitivity to IGF-I by phosphorylating the IGF-I receptor docking protein insulin-receptor-substrate (IRS)-1 in Ser(307) through a pathway involving activation of protein kinases A (PKA) and C (PKC) [51] . The proinXammatory cytokine TNF also induces IGF-I resistance in neurons by altering IGF-I receptor phosphorylation of IRS-2 [128] . Growth hormone regulates IGF-I expression in the brain in an anatomically speciWc manner [49] and leukemia inhibitory factor has been shown to regulate IGF-I levels in peripheral nerve [35] . The cross-talk of IGF-I intracellular signaling with the signaling pathways of other factors may also play an important role in the actions of IGF-I in the nervous system. This is the case of the interaction of IGF-I and nerve growth factor (NGF) in peripheral nerves, where the PI3K/Akt/GSK3 pathway seems to underlay a synergism of these two factors on axonal growth [79] .
Among the factors that aVect IGF-I action in the nervous system, one of the best characterized is the ovarian hormone estradiol. This hormone regulates brain development and function, acting on neurons, synapses and glial cells [3, 29, 57] . Gonadal secretions, including estradiol, act as hormonal signals in brain regions involved in neuroendocrine regulation and the control of sex behavior. In addition, these molecules exert a broad spectrum of actions in many brain areas that are not directly related to reproduction and that are of similar characteristics to those exerted by growth factors. These actions include the modulation of synaptic plasticity, neurogenesis and neuronal survival [54, 90, 131] .
One of the main mechanisms of action of estradiol in the brain, as in other organs, is the activation of nuclear estrogen receptors (ERs). These receptors belong to the steroid/thyroid nuclear receptor superfamily, and once activated homo-or heterodimerize, recruit a cohort of transcriptional cofactors to the regulatory regions of target genes that present Estrogen Response Elements (ERE) sequences and regulate transcription of such genes [99] . In addition, ERs may regulate transcription acting as binding factors of other transcription factors [129] (Fig. 1) . The two mammalian ERs cloned to date, and , are widely distributed through the central nervous system Fig. 1 . Schematic representation of the two major pathways of estrogen signaling. The classical pathway involves the binding of estradiol (E2) to estrogen receptors (ER). This induces estrogen receptor dimerization and translocation to the cell nucleus where estrogen receptors control the transcription of speciWc genes either by binding to Estrogen Response Element (ERE) DNA sequences or by binding to other transcription factors (TF's). In addition, estradiol may activate membrane or cytoplasmic signaling by binding to membrane-associated classical estrogen receptors or to putative estrogen receptor isoforms associated to the plasma membrane (indicated by a question mark in the Wgure). This signaling may activate diVerent secondary messengers, such as ERKs, CREB and PI3K and modulates intracellular calcium concentration. [115] . In addition estradiol may interact with estrogen binding sites, classical ERs or still uncharacterized ERs, in the plasma membrane, the mitochondria and the cytoplasm, exerting rapid eVects on neurons and glial cells. For instance, estradiol may have rapid eVects on neurons via G proteins [97, 110] , activation of the MAPK cascade [11, 125] , activation of the PI3K pathway [21, 90] , the phosphorylation of the cAMP response element binding protein (CREB) [67, 98, 135] and the modiWcation of intracellular calcium levels [10, 25, 94, 105] (Fig. 1) .
All of these hormonal eVects provide multiple potential sites for interactions between the signaling pathways of estradiol and growth factors [125] . Indeed, some of the trophic and plastic eVects of estradiol in neural tissue may be mediated by the activation of growth factor signaling. In accordance with this, several studies have shown that, in speciWc neuronal populations, estrogens regulate the expression of neurotrophins such as brainderived neurotrophic factor (BDNF) [65, 119] and nerve growth factor (NGF) [66, 117] , and the expression of neurotrophin receptors such as p75, trkA [66, 91, 120] and trkB [17] . Estradiol interacts with NGF in the activation of c-jun-kinase 2 in the olfactory bulb [78] and promotes neurotrophin transport in the forebrain [77] . Finally, some estrogen actions in the brain may be mediated by neurotrophins [113] and neurotrophin receptors [27, 100] .
Estradiol is mainly produced in the ovary and reaches the brain from the circulation. In addition, estradiol is formed in the brain from androgen precursors present in plasma and, at least in rodents, also from androgen precursors locally synthesized from cholesterol [72, 114] . Local production of estradiol is important in the developing brain, as inferred for the high levels of expression of aromatase, the enzyme that converts testosterone into estradiol [85] . In the adult rodent brain, the levels of expression of aromatase are substantially reduced, suggesting a decrease in the local formation of estradiol. Interestingly, the synthesis of IGF-I, estradiol and their receptors is induced within damaged brain regions following brain injury, suggesting a possible role for the local production of both factors in brain recovery [8, 52, 68] .
Mechanisms involved in the interaction of estrogen receptors and IGF-I receptor in the brain
In this section we will present evidence of that IGF-I may regulate ER transcriptional activity in neural cells (Section 3.1) and that, in turn, estradiol is able to regulate IGF-I receptor signaling (Section 3.2). The interaction of estradiol and IGF-I may thus involve both transcriptional regulation and rapid membrane-associated signaling. These reciprocal eVects of estradiol on IGF-I receptor activity and of IGF-I on ER activity may be, at least in part, the consequence of an interaction of ER and IGF-I receptor in a macromolecular complex associated to components of the PI3K signaling pathway (Section 3.3).
Regulation of estrogen receptor transcriptional activity by IGF-I
In addition to classical activation of ER by estradiol binding, ER transcriptional activity can be regulated by ligand-independent mechanisms. Intracellular kinase signaling pathways, activated by extracellular growth or trophic factors, regulate the ability of ERs to promote changes in gene expression. IGF-I is one of the extracellular regulators of these kinase pathways that have been shown to promote ER dependent transcription. In diVerent cell lines, including neuroblastoma cells, IGF-I may activate ERs in the absence of estradiol [87, 101] . Whether such eVect takes place in the brain in vivo is still unknown. However, dopamine and other molecular signals activate the unoccupied progesterone receptor to regulate sexual receptivity [5, 13, 88] , indicating that ligand-independent activation of steroid receptors may occur in the brain. In addition, estrogen independent ER activation in the brain is suggested by studies on an ER transgenic strain of mouse with a luciferase transgene driven by a promoter containing estrogen response elements. ER-dependent transgene expression is observed in the brain of these animals when plasma estrogen levels are low and when brain aromatase is inhibited, suggesting that ER can be activated by estrogen-independent mechanisms [31] .
IGF-I regulation of ER transcriptional activity has been extensively studied in non-neuronal tissues and cell lines [82, 89] . These studies have shown that, by phosphorylating ERs and some transcriptional cofactors, the intracellular kinases regulated by IGF-I positively regulate ER mediated gene expression [48, 89] . IGF-I has also been proposed as one of the potential molecules involved in ligand-independent regulation of ERs in the brain [31] . Several components of the IGF-I intracellular signaling system have been shown to aVect ER activity in neuronal cells. The Ras/ MAPK is responsible for the activation of ER dependent transcription in the absence of estradiol [101] in a neuroblastoma cell line.
Recent studies suggest that IGF-I may have a diVerent regulation of the activity of ER in neuronal cells depending on whether the ER ligand is present or not. In absence of estradiol, IGF-I increases ER activity in N2a cells, as in other neuroblastoma cells. In contrast, IGF-I negatively regulates, through activation of the PI3K pathway, estradiol induced activation of ER transcriptional activity in this cell type [92] . The inhibition of ER by IGF-I in N2a cells depends on its ability to regulate GSK3 activity through the PI3K pathway. By opposite, MAPK blockade has no eVect in estradiol induced ER activity [92] . Thus, by using diVerent components of its signaling system, IGF-I may regulate ligand independent and dependent ER transcriptional activity in neuronal cells. Ligand-independent regulation of ER transcriptional activity may explain why ER antagonists block several actions of IGF-I in the brain [7, 40, 104] . In addition, IGF-I modulation of estrogen induced ER transcriptional activity in the presence of estrogen suggest a new mechanism by which IGF-I could be aVecting estrogen actions in the brain.
Activation of IGF-I receptor signaling by estradiol
From the studies reviewed in the previous section we may conclude that IGF-I is able to regulate ER transcriptional activity. In this section we will analyze evidence indicating that, in turn, estradiol is able to regulate IGF-I receptor signaling in the brain.
In vitro and in vivo studies have shown that estradiol may rapidly activate in the brain the two main signal transduction cascades coupled to the IGF-I receptor: the PI3K and the MAPK signaling pathways. It should be noted that in some cases there is an apparent contradiction in the literature among some in vivo and the in vitro studies in the time course of the activation of these two signaling pathways by estradiol. However, this is probably because the time course examined in the in vivo studies does not always include the analysis of short time points. In primary cultures of astroglia, in primary neuronal cultures and in explants of cerebral cortex and hippocampus, estradiol induces a rapid activation of ERK, in the range of minutes [125] . Estradiol-induced activation of ERK in the brain may be also detected in vivo after systemic administration of the hormone and during cyclic Xuctuations of estrogen levels in the estrus cycle [12, [20] [21] [22] . ERK activation may be involved in the induction of neurite arborization of cholinergic neurons by estradiol [38] and in the neuroprotective eVects of the hormone [55, 69, 84, 118] . Estradiol also induces rapid phosphorylation of Akt, one of the main eVectors of the PI3K pathway, in dissociated neurons from the rat cerebral cortex and the hippocampus, in cerebral cortical explants and in the adult rat brain in vivo [20, 21, 76, 130, 136] . Furthermore, IGF-I and estradiol act synergistically to increase Akt activity in the rat brain [21] (Fig. 2) . In contrast, a synergistic eVect of IGF-I and estradiol has not been detected for ERK1 and ERK2 phosphorylation [21] .
Activation of Akt may regulate estradiol-induced synaptic plasticity [136] and may also be involved in the neuroprotective eVects of estradiol [55, 73, 132, 133] . Akt regulates several transcription factors that may be involved in the control of neuronal survival, such as CREB [106] , NF-B [81] and several members of the Forkhead family [16, 83, 121] . In addition, activation of Akt results in the phosphorylation of the Bcl-2 family member Bad and this may suppress Bad-induced cell death [34, 36] . Furthermore, Akt activation enhances Bcl-2 promoter activity [106] and both IGF-I and estrogen induce Bcl-2 expression in neurons. Interestingly, IGF-I receptor activation is necessary for the induction of Bcl-2 by estradiol in the adult brain [32] .
The activation of Akt by estradiol has also implications for the regulation of neuronal function and survival via the modulation of GSK3 activity [23] . Physiological phosphorylation of microtubule-associated proteins by GSK3 may be involved in the regulation of microtubule dynamics, neuritic growth, synaptogenesis and synaptic plasticity [70] .
However, under pathological conditions, GSK3 may be responsible for the hyperphosphorylation of Tau in Alzheimer's disease [86] and its inhibition is associated with the activation of survival pathways in neurons [32] . Interestingly, estradiol regulates the activity of GSK3 and decreases the phosphorylation of Tau in the hippocampus [23] . Immunoprecipitation studies suggest that in this brain region GSK3 forms a macromolecular complex with Tau, -catenin and the p85 subunit of the PI3K and another complex with ER and -catenin (Fig. 3) . Estradiol increases the amount of phosphorylated GSK3 associated to the Wrst complex and reduces the amount of -catenin associated to the second complex (Fig. 3) . By the modulation of these macromolecular interactions, between cytoskeletal and signaling proteins, estradiol may regulate microtubule dynamics, synaptic plasticity and neuronal survival [23] .
Molecular interaction of estrogen receptor alpha and IGF-I receptor
The reciprocal eVects of IGF-I on ER activity and of estradiol on IGF-I receptor signaling analyzed in the two previous sections may be, at least in part, the consequence of an interaction of ER and IGF-I receptor in a macromolecular complex associated to components of the PI3K signaling pathway.
Immunohistochemical analyses have shown that ERs and IGF-I receptor colocalize in diVerent neuronal and glial populations in the rat central nervous system in vivo [19, 55] . Immunoprecipitation studies have also been conducted to assess the possible interaction between ERs and the IGF-I receptor in the brain (Fig. 4) . Estradiol administration to adult ovariectomized rats results in a transient increase in the association between IGF-I receptor and ER in the hypothalamus [93] . The maximal eVect is seen between 1 and 3 h after the administration of the hormone. However, it should be mentioned that shorter time periods than 1 h were not examined, and therefore the kinetics of the interaction is largely unknown. The association returns to control levels 24 h after hormone treatment. The interaction is speciWc for the subtype of ERs and is coincident in time with the increase in tyrosine phosphorylation of IGF-I receptor, suggesting a possible causal relationship (Fig. 4) . Estradiol also increases the interaction between p85 and IRS-1 [93] , one of the Wrst events in the signal transduction of the IGF-I receptor [9, 80] , further suggesting that the increase in IGF-I receptor phosphorylation induced by estradiol reXects functional activation of this receptor. In addition ER interacts with other components of the IGF-I receptor signaling pathway, such as the p85 subunit of the PI3K [93] . This interaction is present in control ovariectomized animals and is increased 3 h after systemic estradiol treatment. A similar estradiol-induced association of ER and p85 occurs in the mammary cancer cell line MCF-7 [28] and in human vascular endothelial cells [116] .
The association of ER with p85 suggests that the eVect of estradiol on the interaction of p85 with IRS-1, -catenin and Tau [23, 93] may be mediated by the association of ER with the macromolecular complex formed by the PI3K. Interestingly, the interaction between estrogen and IGF-I systems in the hypothalamus seems to be reciprocal, since the intracerebroventricular administration of IGF-I also resulted in an increase in the levels of association between ER and IGF-I receptor [93] . These Wndings suggest that the interaction of ER with IGF-I receptor is part of the mechanisms involved in the signaling of both IGF-I and estradiol in the brain. This may explain why ER antagonists or antisense oligonucleotides against ER are able to block IGF-I eVects on neuronal survival, dendritic growth and neurogenesis [7, 40, 104] as well as why the inhibition of IGF-I receptor or IGF-I receptor signaling blocks the action of estradiol on diVerent neural events [7, 24, 42, 109] .
All these Wndings suggest that ER may aVect IGF-I actions in the brain by a direct interaction with some of the components of IGF-I signaling. A summary of these interactions is shown in Fig. 5 . Estradiol regulates the activity of protein kinases, increasing IGF-I receptor and Akt phosphorylation. By aVecting Akt phosphorylation estradiol may exert part of its metabolic, developmental, neuroendocrine and neuroprotective eVects. Furthermore, estradiol regulates the activity of GSK3 , which in turn regulates Tau phosphorylation, and the association of p85 andcatenin with Tau. By these mechanisms, estradiol may aVect neuritic growth, synaptic formation, neuronal survival and neuronal plasticity (Fig. 5 ).
An interesting and unsolved question is the possible subcellular localization in which the interactions of ER with IGF-I receptor and the IGF-I receptor associated signaling complex occur. Although IGF-I receptor immunoreactivity has been detected in neuronal and glial cell nuclei [62] there is little evidence that other components of the IGF-I signaling system may reach a nuclear localization. In contrast, several recent reports have demonstrated localization of ER , or ERs subtypes structurally close to classical ER , in the cytoplasm and plasma membrane of neurons and glial cells [96, 103, 124] . Therefore, it is possible that a fraction of ERs localized in the cytoplasm or associated to speciWc membrane domains, such as caveolae [125] , may be able to interact with Fig. 3 . Schematic representation of the eVect of estradiol on two macromolecular complexes identiWed in the hippocampus of ovariectomized rats, based on Ref. [23] . In one of these complexes (a) Tau, GSK3 , -catenin ( -Cat) and the regulatory subunit of PI3K (p85) are associated. Systemic estradiol administration increases the amount of -catenin and P85 associated to Tau. Whereas total GSK3 diminished in the complex; the hormone induced an increase in the association of Tau with the fraction of GSK3 phosphorylated on serine. In a second complex (b), estrogen receptor (ER), is initially associated with GSK3 and -catenin. Estradiol treatment reduces the amount of -catenin associated to the complex, allowing its interaction with transcription factors (TCF) in the cell nucleus. By regulating interactions of Tau, GSK3, -catenin and p85, estradiol may aVect cytoskeletal reorganization and synaptic remodeling. By the modulation of the interactions of -catenin, GSK3 and estrogen receptors, estradiol may regulate the transcription of genes involved in neuronal survival.
IGF-I receptor and other components of the IGF-I signaling factory. However, the possible interaction of IGF-I receptor with membrane ERs has not been adequately explored.
Functional consequences of the interactions of estradiol and IGF-I in the brain
Evidence for the functional interaction of estradiol and IGF-I and their signaling systems have been obtained in developing neural cells. IGF-I receptors are involved in the eVects of estradiol on the promotion of neuronal survival and diVerentiation in developing neurons. In turn, ERs are involved in the eVects of IGF-I in these parameters (Section 4.1). Interactions of IGF-I and estradiol signaling have also been detected in the adult brain, where ERs appear to be involved in the eVects of IGF-I on adult neurogenesis in the hippocampus (Section 4.2) and estradiol and IGF-I interact in the regulation of synaptic plasticity in neuroendocrine areas (Section 4.3). Furthermore, interactions of estradiol and IGF-I signaling may be involved in the neuroprotective eVects of these two factors in the adult brain (Section 4.4).
Interaction of IGF-I receptor and estrogen receptors on developing neurons
The interactions of estrogen and IGF-I are relevant for brain development. An interaction between these two factors may contribute to the development of structural sex diVerences in the brain by the regulation of the survival and diVerentiation of developing neurons in brain areas involved in the regulation of neuroendocrine events and reproduction [26] . The Wrst evidence of such an interaction was obtained by Dominique Toran-Allerand et al. [123] , showing a synergic eVect of estrogen and insulin on neuritic growth in fetal rat and mouse brain explants. Although IGF-I was not directly tested in this study, it was proposed that the eVect of insulin could be mediated by the activation of IGF-I receptors. Several years latter, the laboratory of Adriana Maggi [87] reported that insulin and IGFs promote the elongation of neurites and growth arrest of a neuroblastoma cell line, but only when these cells were transfected with ER . Furthermore, these authors provided evidence of a modulation of ER-activated promoters by IGF-I [87] . Further studies determined that insulin can activate the unliganded ER via the ras-pathway [1, 102] and that this activation involved the N-terminal activation function 1 (AF-1) domain of the ER [101] (see also Section 3.1).
Several studies have demonstrated an interdependence of ERs and IGF-I receptor in the promotion of the survival and diVerentiation in primary cultures of developing hypothalamic neurons [17, 26, 40] . Both estradiol and IGF-I promote neuronal survival and diVerentiation in primary neuronal cultures grown in a deWned medium deprived of serum and hormones. In these cultures, the induction of neuronal survival and diVerentiation by IGF-I was prevented by inhibiting the synthesis of ER , using a speciWc antisense oligonucleotide [40] . The eVect of IGF-I was also prevented by the ER antagonist ICI 182,780 [40] . In turn, the promotion of neuronal survival and diVerentiation by estradiol was prevented by blocking the synthesis of IGF-I in the cultures using a speciWc IGF-I antisense oligonucleotide [40] , as well as by the pharmacological blockade of the MAPK and the PI3K signaling pathways, both activated by the IGF-I receptor [55] . Therefore, ER mediates eVects of IGF-I and IGF-I receptor mediates eVects of estradiol on hypothalamic neurons. Similar results have been obtained in PC12 cells transfected with ER . Both estradiol and IGF-I increased neuritic growth and antagonists of ERs and IGF-I receptor blocked the eVect of both factors, indicating that ER mediates eVects of IGF-I and IGF-I receptor mediates eVects of estradiol on neuritic growth in PC12 cells [122] .
Interaction of IGF-I and estrogen receptors in the regulation of adult neurogenesis
Activation of ERs by IGF-I may be involved in the actions of this factor in the regulation of adult neurogenesis in vivo in the rodent hippocampus. Neural precursors located in the subgranular zone of the dentate gyrus of the hippocampus proliferate in adult rodents. The newly generated neurons are functional, integrate in hippocampal circuits and may be involved in certain forms of hippocampaldependent learning. IGF-I and estradiol are among the molecules that have been identiWed as modulators of adult neurogenesis. The intracerebroventricular administration of the ER antagonist ICI 182,780 blocks IGF-I-induced neurogenesis in adult ovariectomized rats [104] , suggesting that ERs are involved in the action of IGF-I on adult hippocampal neurogenesis. This interaction of IGF-I with ERs may directly occur in the proliferating cells, since they express receptors for both IGF-I and estrogen [75, 104] .
Interaction of IGF-I and estrogen receptors in the regulation of synaptic plasticity in the adult brain
As an endocrine signal, IGF-I represents a link between the growth and reproductive axes and the interaction between IGF-I and estradiol in the brain is of particular physiological relevance for the regulation of growth, sexual maturation and adult neuroendocrine function. Functional interactions between estrogen and IGF-I receptor have been reported in pituitary cells [4] and in neuroendocrine brain areas. These include interactions on (1B)-adrenoceptor expression in the hypothalamus and preoptic area, on luteinizing hormone release and on estradiol-dependent reproductive behavior [41, 42, 107, 108] . These studies are reviewed by Etgen et al. in this issue [43] . One brain area involved in neuroendocrine control where interactions of estrogen and IGF-I have been reported is the hypothalamic arcuate nucleus, a key center for neuroendocrine regulation of the growth and reproductive axes and for the control of food intake and energy balance. This nucleus shows estrogen-induced and estrous cycle-related plastic changes in synaptic connectivity and glial-neuronal interactions in female rodents [57] . During the preovulatory and ovulatory phases of the estrous cycle there is a transient disconnection of axo-somatic GABAergic synapses on the arcuate somas of adult female rats. The synaptic remodeling is induced by estradiol and is linked to plastic modiWcations in astroglial processes [57] . Estradiol increases IGF-I accumulation in the arcuate nucleus during the estrous cycle [39, 57] . IGF-I levels increase in the afternoon of proestrus and remain high in the morning of estrus. This eVect may be in part mediated by the over-expression of insulin-like growth factor binding protein-2 by hypothalamic tanycytes, specialized glial cells that express IGF-I receptor and accumulate IGF-I from the cerebrospinal Xuid [18, 111] . Furthermore, results from in vivo experiments (3) phosphorylation. E2 decreases GSK3 activity (4), which in turn decreases Tau phosphorylation (6) . In addition, estrogen receptor (ER ) interacts with GSK3 (4) and estradiol treatment modulates the interaction between ER , IGF-I receptor (1) and p85 (2) . The association of p85 (5) and -catenin (7) with Tau is also increased upon estradiol treatment in the brain. using intracerebroventricular infusion of speciWc receptor antagonists have shown that both estrogen receptors and IGF-I receptor are involved in the induction of synaptic and glial plastic modiWcations in the arcuate nucleus during the estrous cycle [24, 45, 46] . Under control conditions, the number of synaptic inputs on arcuate neuronal somas of cycling female rats decreased between the morning of proestrus and the morning of estrus. This phasic synaptic and glial remodeling is blocked by the administration in the lateral cerebral ventricle of an IGF-I receptor antagonist, the peptide JB1. In contrast, JB1 does not aVect the number of synapses in proestrus rats, suggesting that IGF-I receptor activation is necessary for the estrogen-dependent synaptic plastic changes but not for the normal maintenance of synaptic inputs [46] .
Interaction of IGF-I receptor and estrogen receptors on neuroprotection
IGF-I and estradiol have neuroprotective properties and prevent neuronal cell death in diVerent experimental models of neurodegenerative diseases. The interaction of IGF-I and estradiol in neuroprotection has been assessed in ovariectomized rats in vivo, using systemic administration of kainic acid to induce degeneration of hippocampal hilar neurons [7] , an experimental model of excitotoxic cell death. Both the systemic administration of estradiol and the intracerebroventricular infusion of IGF-I prevent hilar neuronal loss induced by kainic acid. The neuroprotective eVect of estradiol is blocked by the intracerebroventricular infusion of the IGF-I receptor antagonist JB1, while the neuroprotective eVect of IGF-I is blocked by the intracerebroventricular infusion of the ER antagonist ICI 182,780 [7] . Similar results have been obtained in ovariectomized rats after the unilateral infusion of 6-hydroxdopamine into the medial forebrain bundle to lesion the nigrostriatal dopaminergic pathway [109] a model of Parkinson's disease. Pretreatment with estrogen or IGF-I signiWcantly prevents the loss of substantia nigra compacta neurons and the related motor disturbances. Blockage of IGF-I receptor by intracerebroventricular JB-1, attenuates the neuroprotective eVects of both estrogen and IGF-I [109] . Furthermore, the neuroprotective action of estradiol against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in the nigro-striatal system of male mice is associated to the regulation of IGF-I receptor signaling [33] . These Wndings suggest that the neuroprotective actions of estradiol and IGF-I after brain injury depend on the coactivation of both estrogen receptors and IGF-I receptor in neural cells.
Role of neurons and glial cells in the interaction of estradiol and IGF-I
The molecular interactions of ER and IGF-I receptor, reviewed in Section 3.3, as well as the results of immunohistochemical analyses showing that ERs and IGF-I receptor colocalize in diVerent neuronal and glial populations in the rat central nervous system [19, 55] suggests that estradiol and IGF-I may directly interact and exert their eVects on each cell type without the participation of the other cellular component. Indeed, in vitro studies reveal interactions of estradiol and IGF-I in pure glial cultures and in pure neuronal cultures. In astroglial cell cultures, estradiol interacts with several growth factors, including IGF-I, in the regulation of the expression of glial Wbrillary acidic protein (GFAP) and vimentin [6] . In turn, as mentioned in Section 4.1, estradiol and IGF-I interact in the promotion on neuronal survival and diVerentiation in pure neuronal cultures [40] and in the promotion of neuritogenesis in neuroblastoma cells [87, 122] .
Although these in vitro studies demonstrate that interactions of estradiol and IGF-I may occur independently in both neurons and glial cells, it is probable that in vivo the actions of IGF-I or estradiol in one cell type may aVect the actions of estradiol or IGF-I, respectively, in the other cell type. Neuron-glia interactions are essential for brain function [2] and these interactions may also be involved in the eVects of estradiol and IGF-I in the brain [52, 56, 59, 60] . Carrer et al. [17, 26] have shown that estradiol induces an increase in axonal growth and in the expression of TrkB and IGF-I receptor in ventromedial hypothalamic neurons derived from male rats. However, this eVect is only detected when neurons are cultured in the presence of conditioned media from glial cells from target regions. This suggests that growth factors released by glia are involved in the neuritogenic eVect of estradiol and that IGF-I receptor may be involved in this eVect.
Another example of neuron-glia interactions in the mediation of the actions of estradiol and IGF-I in the brain is provided by the synaptic remodeling associated to the estrous cycle that occurs in the hypothalamic arcuate nucleus [57, 58] . As mentioned in Section 4.3, the synaptic remodeling is induced by estradiol, is linked to plastic modiWcations in astroglial processes and depend on both ERs and IGF-I receptor. Arcuate neurons express estrogen and IGF-I receptors [62, 115] and may be, therefore, a direct target for both estradiol and IGF-I. IGF-I may aVect pre-and/ or postsynaptic mechanisms, since ultrastructural studies have shown that IGF-I receptor is present both in axosomatic presynaptic terminals as well as in neuronal somas of the rat arcuate nucleus [62] . In addition, arcuate astrocytes are also a target for IGF-I, since they also express IGF-I receptor [62] . Arcuate astrocytes appear to be directly involved in the regulation of synaptic inputs to arcuate neurons, since synaptic disconnection of arcuate neurons in estrous females is accompanied by an increased extension of GFAP immunoreactive astrocytic processes, detected by light microscopy, and by an increase in the escheatment of neuronal surfaces by astrocytic processes, detected by electron microscopic analysis [57, 58] . Interestingly, studies on hypothalamic tissue fragments from ovariectomized rats have shown that IGF-I receptor activation is needed for the induction of GFAP changes by estrogen in the arcuate nucleus [45] . In addition, tanycytes may play an important role in the interaction of estradiol and IGF-I for the regulation of synaptic plasticity, regulating the levels of IGF-I in the arcuate nucleus [39, 45, 47] . Indeed, the administration of the IGF-I receptor antagonist JB1 in the rat lateral cerebral ventricle is able to block both the accumulation of IGF-I by arcuate nucleus tanycytes and estrogen-induced synaptic plasticity [45, 47, 60] .
Glial cells may also be involved in the interaction of estradiol and IGF-I on neuroprotection (see Section 4.4), since brain injury results in the induction of the synthesis of IGF-I and estradiol by reactive astrocytes [50, 63, 74] and in the upregulation of the expression of ERs, IGF-I receptors and IGF-binding proteins in reactive glia [8, 14, 30, 53] . Therefore, estradiol and IGF-I released by reactive glia may act directly on these cells or in neighboring neurons, regulating reactive gliosis, neuronal survival and the reorganization of neural tissue after injury.
Conclusions
The studies reviewed here indicate that the mechanisms of intracellular signaling of IGF-I and estradiol are intimately associated in the nervous system. IGF-I receptor seems to be part of the signaling mechanism of estradiol in the brain and the hormone activates IGF-I receptor signaling in primary neuronal cultures, in primary glial cell cultures, in explant brain cultures and in several brain regions in vivo (Fig. 6) . In turn, ER appears to be part of the signaling mechanism of IGF-I in the brain and IGF-I regulates ER transcriptional activity in neuroblastoma cells (Fig. 6) . The interaction between IGF-I and estradiol appears to be relevant during brain development and in adulthood and participate in the regulation of neuronal diVerentiation, neuronal survival, synaptic connectivity, neural plasticity, neuroendocrine regulation and behavior. The coupling of the signaling pathways of IGF-I and estradiol in neural cells may act as a coincidence signal detector to timely coordinate the endocrine and paracrine eVects of both factors. Fig. 6 . SimpliWed summary of the reciprocal interactions of ER and IGF-I receptor (IGF-IR) in the nervous system. Estradiol, acting on ER , is able to activate IGF-I receptor signaling probably by non-genomic mechanisms (1). In turn, IGF-I, by the activation of IGF-I receptor signaling, regulates the transcriptional activity of ER (2) . The Wrst mechanism has been detected in primary neuronal cultures, primary glial cell cultures, explant brain cultures and in diVerent brain regions in vivo. The second mechanism has been explored in neuroblastoma cells only.
